Navigation Links
Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
Date:7/14/2011

LA JOLLA, Calif., July 14, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has added Gregory Hannon, Ph.D. to its Scientific Advisory Board (SAB). The addition of Dr. Hannon, a researcher whose work has involved the molecular identification and characterization of the microRNA pathway, increases SAB membership to six pioneers in this area of scientific research.

"We are delighted to add Greg to our SAB as he brings new insights to the already outstanding group of scientific advisors aiding us in the understanding of microRNA biology," said Neil W. Gibson, Ph.D., chief scientific officer of Regulus. "Greg is a world-renowned researcher with expertise in small regulatory RNAs and an understanding of the molecular mechanisms by which they operate."

"The Regulus SAB includes many of the world's thought leaders in the field of microRNA," said David Baltimore, Ph.D., professor of biology at the California Institute of Technology and Director of Regulus as well as Chairman of Regulus' SAB. "Greg's seminal discoveries in the field of non-coding RNAs include the identification of the enzyme Dicer which cleaves double stranded RNA to produce small RNAs like microRNA. This discovery contributed to Science magazine naming small RNAs the 2002 Breakthrough of the Year."

Dr. Hannon's laboratory has identified and characterized many of the major biogenesis and effector complexes for microRNAs and small interfering RNAs. In addition, the Hannon lab strives to understand the biology of cancer cells, with a focus on the roles of small RNAs as oncogenes and tumor suppressors.

In addition to Dr. Hannon, Regulus' SAB members are:

  • David Baltimore, Ph.D., professor of biology at the California Institute of Technology, member of t
    '/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 01, 2015 Research and Markets ( ... Dermatology Devices Market by Type, by End User - Forecast ... Asian Dermatology Devices market is estimated to grow at a ... holds a larger share in the Dermatology devices ... . The Asian Dermatology Devices market holds a high ...
(Date:5/1/2015)... Colo. , May 1, 2015   Heska Corporation ... or the "Company"), a provider of advanced veterinary diagnostic ... Robert Grieve , Executive Chair, will present at the 16th ... (PT), on May 13, 2015. The conference will be held ... Angeles, CA. Heska management will be available during ...
(Date:5/1/2015)... 2015  CytRx Corporation (CYTR), a biopharmaceutical research ... financial results for the three months ended March ... accomplishments and upcoming milestones for its clinical development ... the early months of 2015, including the announcement ... aldoxorubicin in patients with soft tissue sarcoma, and ...
Breaking Medicine Technology:Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... , SAN DIEGO , Feb. 2 ADVENTRX ... Principal Executive Officer, Brian M. Culley , will present at the ... 2010 , at 10:30 a.m. Eastern time , in the Park ... conference is being hosted by the Biotechnology Industry Association. , Interested parties ...
... , , ... February 2 ReportsandReports announce to,have Biosimilars Series: Forecast ... The high cost and utilization of ... provides considerable momentum to,the emerging biosimilars market. With a biosimilar ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9 2ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report 2ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report 3
(Date:5/2/2015)... 02, 2015 As a nonsurgical ... of the face, neck and décolleté, radiofrequency energy ... real potential for the success of vulvovaginal rejuvenation. ... Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory ... concluded that ThermiGyn’s temperature controlled radio frequency, specifically ...
(Date:5/2/2015)... success that Veatch Dental Consulting has had over the years, ... Shields to the team. With Neida and Alex on board, ... working with dentists to ensure their success. , Neida Miranda ... She was certified as dental assistant from Texas State Technical ... the importance of oral hygiene to patients, Neida was moved ...
(Date:5/1/2015)... May 02, 2015 The Venetian on ... http://www.thevenetiangracebay.com , and it is elegant and sophisticated, ... white and attractive turquoise hues of Grace Bay Beach. ... seven percent of leisure travelers used their smartphones throughout ... were used in the planning and researching and continued ...
(Date:5/1/2015)... Anaheim, CA (PRWEB) May 01, 2015 ... Ethos Award for the successful repositioning of its flagship ... its company brand with a new name, new logo, ... The DSA Ethos Awards are designed to identify and ... at its best. , “DSA congratulates Jusuru International ...
(Date:5/1/2015)... RESTON, Va. (PRWEB) May 01, 2015 ... the nation’s leading nonprofit authority on the use of ... served as a key contributing resource to the United ... the use of electronically readable cards in Medicare. The ... Beneficiaries and Providers ” was released to the public ...
Breaking Medicine News(10 mins):Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... Presentation to highlight milestones including phase III development of ... What: Horizon Therapeutics, Inc. is pleased to announce that ... M.D., Ph.D., chief executive officer, will ... including its recent completion of Series C financing, and ...
... Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study,Have Been Dosed With ... Four Have Been Dosed for More Than ... 8:00 a.m. E.T. ... at http://www.isispharm.com , CARLSBAD, Calif., Oct. 5 Isis,Pharmaceuticals, Inc. (Nasdaq: ...
... knows about the,FDA,s impending ban on children,s cold ... scramble to find other ways to alleviate their ... recently,introduced into the U.S. -- offers a safe ... According to the FDA, popular medicines such ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... U.S. may,be breathing its last gasps, as the ... Passage in the House is expected to be ... past six years, this legislation would,finally ban asbestos, ... asbestos, most deadly cancer, mesothelioma (meso), and other,asbestos-related ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the appointment ... Company,s new independent auditor effective October,2, 2007. BPM, ... the Audit Committee of the Company,s Board of ... with several,public accounting firms. BPM replaces PricewaterhouseCoopers LLP. ...
Cached Medicine News:Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 3Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 4Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 5Health News:Nosefrida Nasal Aspirator - A Parent's Alternative to Medicines on the Verge of FDA Ban 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 3Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 4
Intermittent catheter...
Intermittent catheter...
... new Finnpipette Focus from Thermo Labsystems was ... performance. Advanced features such as the ... volume adjustment on microvolumes help to define ... channel pipettes. The new interchangeable handle plate ...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
Medicine Products: